Table 1.
Pioglitazone (n = 6) | Placebo (n = 8) | Total (n = 14a) | p valueb | |
---|---|---|---|---|
Demographics | ||||
Age | 49.7 (6.6) | 43.3 (6.0) | 46.0 (6.8) | 0.08 |
Male | 6 (100%) | 7 (87.5%) | 13 (92.9%) | 0.37 |
Black/African Americanc | 5 (83.3%) | 4 (50.0%) | 9 (64.3%) | 0.40 |
Education (years) | 13.3 (2.4) | 12.5 (4.0) | 12.9 (3.3) | 0.66 |
Smoker | 5 (83.3%) | 5 (62.5%) | 10 (71.4%) | 0.39 |
Fagerstrom Score | 3.2 (3.1) | 3.0 (1.7) | 3.1 (2.4) | 0.90 |
Family history densityd | 0.2 (0.1) | 0.1 (0.1) | 0.1 (0.1) | 0.27 |
Alcohol-related measures | ||||
Avg. drinks/drinking day | 10.4 (4.3) | 14.3 (4.0) | 12.6 (4.4) | 0.11 |
Heavy drinking days | 67.5 (27.3) | 76.4 (15.0) | 72.6 (20.7) | 0.45 |
ADSe score | 19.2 (9.0) | 12.9 (6.4) | 15.6 (8.0) | 0.15 |
PACSf craving | 16.3 (8.6) | 7.3 (3.5) | 11.1 (7.5) | 0.05 |
Psychological characteristics | ||||
Current anxiety disorder | 1 (16.7%) | 2 (25.0%) | 3 (21.4%) | 0.71 |
Current mood disorder | 0 (0.0%) | 1 (12.5%) | 1 (7.1%) | 0.37 |
Current substance use disorderg | 1 (16.7%) | 0 (0.0%) | 1 (7.1%) | 0.23 |
CTQh total score | 41.5 (20.4) | 41.6 (9.2) | 41.6 (14.3) | 0.98 |
Neuroticism score | 53.3 (7.2) | 54 (6.8) | 53.7 (6.7) | 0.86 |
CPRSi anxiety | 12.5 (7.9) | 9.9 (6.6) | 11 (7.0) | 0.51 |
CPRS depression | 13.7 (8.3) | 13.1 (7.2) | 13.4 (7.4) | 0.90 |
Of the 14 subjects, 13 completed the entire protocol while 1 subject completed the scripts challenge but not the LPS challenge
Based on a chi-square test for categorical measures, and a t test for continuous measures
The remaining subjects were White/Caucasian (4) and Asian (1)
Calculated as the proportion of first- and second-degree relatives known to have been treated for alcohol abuse or have alcohol use–related problems, as measured by the Family Tree Questionnaire (FTQ)
Alcohol Dependence Scale
Penn Alcohol Craving Scale
Substances other than alcohol
Childhood Trauma Questionnaire
Comprehensive Psychopathological Rating Scale